Developer docs
API playgroundTry for free, no card

Search company profiles

Nucleo

Full company profile

uuid004otis

Namestring
Nucleo
Legal namestring
Nucleo Research
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Nucleo Research ("Nucleo") is an early-stage healthcare AI company that automates CT scan analysis for oncology care. The platform delivers three integrated capabilities: automatic body composition and sarcopenia assessment (quantifying fat and muscle mass), precise tumor lesion sizing, and automated target vs. non-target lesion classification per RECIST criteria. Its stated value proposition is faster-than-manual segmentation with high agreement (reported as 95%) between Nucleo's outputs and expert radiologist analysis, addressing the time and consistency bottlenecks in oncology imaging workflows.

The underlying technology is computer vision applied to CT/DICOM medical images, built on NVIDIA-powered infrastructure. The product is delivered as a software platform targeted at hospitals and oncology departments, with no disclosed API or SDK and no disclosed regulatory clearance (e.g., FDA pathway). Distribution is direct enterprise sales via a consultative demo motion (Cal.com booking), and the company is backed by Y Combinator and works with hospitals in the US and internationally. All public-facing technical claims (accuracy, speed) are vendor-reported; no independent validation, peer-reviewed studies, or patents are disclosed in the source material.

Nucleo is privately held, headquartered in San Francisco, founded in 2025, and operates with 1–10 employees. Its only disclosed funding event is a $500,000 Y Combinator-led round dated December 3, 2025. The revenue model is best characterized as quote-based enterprise SaaS for healthcare institutions, though pricing is not publicly disclosed and the company is most likely at a pre-revenue or early-pilot commercial stage given its recency, headcount, and capital base.

Short descriptiontext

Nucleo is an AI-powered medical imaging platform that automates CT scan analysis for oncology care, delivering body composition assessment, tumor lesion sizing, and RECIST-compliant lesion classification to hospitals in the US and internationally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
AI medical imaging, CT scan analysis, oncology diagnostics, tumor segmentation, radiology automation
Industry2 codes
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACALAK
Teleradiology Platforms & Reading Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
AI Oncology Imaging Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1AI Diagnostics Platform
TypeSubscription Recurring
Description

Automated cancer diagnostics solution for healthcare providers, likely delivered as a software-as-a-service platform integrated into clinical workflows.

nucleoresearch.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Nucleo offers an AI-powered software platform that automates analysis of CT scans for oncology care. The platform performs three core functions: (1) automatic detection and quantification of body composition (fat and muscle mass) for sarcopenia assessment, (2) precise and consistent measurement of tumor lesions, and (3) automated classification of target vs. non-target lesions according to RECIST criteria. It is sold as a recurring software platform to hospitals and oncology providers, with reported 95% agreement between its outputs and expert radiologists.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Faster than manual segmentation
+1 more record
Product overview1 text field

Nucleo is a unified automated cancer diagnostics platform that analyzes CT scans for oncology care. The platform offers three integrated capabilities: (1) Body Composition and Sarcopenia Assessment for automatic detection and quantification of fat and muscle mass in CT scans; (2) Tumor Lesion Sizing for precise and consistent measurement of tumor lesions; and (3) Target vs. Non-Target Lesion Classification for automated classification of lesions according to RECIST criteria. The system operates faster than manual segmentation with 95% agreement between Nucleo and expert radiologists.

Product and service1 record
1Nucleo
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or Integration
Description

NVIDIA is listed as an industry leader powering Nucleo's technology. NVIDIA provides GPU computing infrastructure and likely AI/ML tools that support the company's CT scan analysis platform.

2US Hospitals
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Nucleo works with leading hospitals in the US, deploying its automated cancer diagnostics technology in clinical oncology workflows.

nucleoresearch.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Nucleo partners with hospitals worldwide, extending its automated cancer diagnostics platform to international healthcare markets.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Annalise.ai provides comprehensive AI detection and quantification across CT and X-ray modalities, with oncology-relevant findings among its 130+ findings. Comparable in delivering CT AI analytics for hospital radiology and oncology workflows.

TypeBroad incumbent
Description

RadNet operates one of the largest US imaging center networks and, through its DeepHealth subsidiary, develops AI tools for radiology including oncology. Comparable in deploying AI for CT scan analysis and oncology workflows, but as a large incumbent with diagnostic center operations.

TypeDirect peer
Description

Viz.ai provides AI-powered imaging analytics (notably stroke and oncology) that integrate into hospital workflows to triage and coordinate care. Comparable to Nucleo in deploying AI imaging models to hospital radiology/oncology teams and using subscription enterprise sales.

TypeDirect peer
Description

Aidoc is a leading AI radiology platform that analyzes CT and other imaging to flag acute findings (e.g., stroke, PE, oncology) for radiologists. Directly comparable to Nucleo in applying AI to CT scans for clinical oncology workflows and selling into hospital systems on a subscription basis.

TypeDirect peer
Description

Paige applies AI to pathology and oncology imaging for cancer detection and tumor characterization, with FDA-cleared products. Directly comparable to Nucleo in using AI for cancer diagnostics from medical images and targeting oncology clinical workflows in hospitals.

TypeDirect peer
Description

Riverain (ClearRead) offers AI tools that analyze chest CT and X-ray for nodule detection and improved reader efficiency, integrating into hospital PACS workflows. Comparable to Nucleo in applying AI to CT scans in oncology-relevant clinical workflows.

TypeDirect peer
Description

Arterys (now Tempus AI Radiology) provides a cloud-native AI imaging analytics platform with FDA-cleared oncology and cardiac imaging applications. Comparable in delivering automated quantitative analysis of CT/MR images to hospital radiology departments via SaaS.

TypeDirect peer
Description

Perspectum develops AI-driven medical image quantification tools (e.g., body composition, organ fat/muscle) deployed in hospital and research settings. Comparable to Nucleo's body composition and quantitative oncology imaging analytics.

9Tempus AI
TypeBroad incumbent
Description

Tempus is a broad AI-driven precision medicine company spanning oncology data, sequencing, and imaging analytics (including Arterys). Comparable in applying AI to oncology imaging and clinical decision support, though operating at much larger scale across multiple modalities.

TypeDirect peer
Description

Quibim is a medical imaging AI company that extracts quantitative biomarkers (including body composition and tumor characterization) from CT and MRI for oncology and other specialties. Closely comparable to Nucleo's body composition, tumor sizing, and lesion classification use cases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nucleo

AI Oncology Imaging Softwarenucleoresearch.com

Nucleo is an AI-powered medical imaging platform that automates CT scan analysis for oncology care, delivering body composition assessment, tumor lesion sizing, and RECIST-compliant lesion classification to hospitals in the US and internationally.

What Nucleo does

Nucleo Research ("Nucleo") is an early-stage healthcare AI company that automates CT scan analysis for oncology care. The platform delivers three integrated capabilities: automatic body composition and sarcopenia assessment (quantifying fat and muscle mass), precise tumor lesion sizing, and automated target vs. non-target lesion classification per RECIST criteria. Its stated value proposition is faster-than-manual segmentation with high agreement (reported as 95%) between Nucleo's outputs and expert radiologist analysis, addressing the time and consistency bottlenecks in oncology imaging workflows.

The underlying technology is computer vision applied to CT/DICOM medical images, built on NVIDIA-powered infrastructure. The product is delivered as a software platform targeted at hospitals and oncology departments, with no disclosed API or SDK and no disclosed regulatory clearance (e.g., FDA pathway). Distribution is direct enterprise sales via a consultative demo motion (Cal.com booking), and the company is backed by Y Combinator and works with hospitals in the US and internationally. All public-facing technical claims (accuracy, speed) are vendor-reported; no independent validation, peer-reviewed studies, or patents are disclosed in the source material.

Nucleo is privately held, headquartered in San Francisco, founded in 2025, and operates with 1–10 employees. Its only disclosed funding event is a $500,000 Y Combinator-led round dated December 3, 2025. The revenue model is best characterized as quote-based enterprise SaaS for healthcare institutions, though pricing is not publicly disclosed and the company is most likely at a pre-revenue or early-pilot commercial stage given its recency, headcount, and capital base.

Nucleo firmographics

Firmographics
Name
Nucleo
Legal name
Nucleo Research
Website
https://nucleoresearch.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
1–10 employees
Short description
Nucleo is an AI-powered medical imaging platform that automates CT scan analysis for oncology care, delivering body composition assessment, tumor lesion sizing, and RECIST-compliant lesion classification to hospitals in the US and internationally.
Ownership category
akta.pro rank

Nucleo industry classification

Industry
Product category
AI Oncology Imaging Software
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACALAK
Teleradiology Platforms & Reading Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

Keywords

  • AI medical imaging
  • CT scan analysis
  • Oncology diagnostics
  • Tumor segmentation
  • Radiology automation

Where Nucleo is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Markets served

Nucleo business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. AI Diagnostics Platform: Automated cancer diagnostics solution for healthcare providers, likely delivered as a software-as-a-service platform integrated into clinical workflows.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Nucleo product offering

Product offering

Core offering

Nucleo offers an AI-powered software platform that automates analysis of CT scans for oncology care. The platform performs three core functions: (1) automatic detection and quantification of body composition (fat and muscle mass) for sarcopenia assessment, (2) precise and consistent measurement of tumor lesions, and (3) automated classification of target vs. non-target lesions according to RECIST criteria. It is sold as a recurring software platform to hospitals and oncology providers, with reported 95% agreement between its outputs and expert radiologists.

Product overview

Nucleo is a unified automated cancer diagnostics platform that analyzes CT scans for oncology care. The platform offers three integrated capabilities: (1) Body Composition and Sarcopenia Assessment for automatic detection and quantification of fat and muscle mass in CT scans; (2) Tumor Lesion Sizing for precise and consistent measurement of tumor lesions; and (3) Target vs. Non-Target Lesion Classification for automated classification of lesions according to RECIST criteria. The system operates faster than manual segmentation with 95% agreement between Nucleo and expert radiologists.

Differentiator

Problem solved

Functional benefit

Products and services

  • Nucleo

Quantifiable outcome

  • Faster than manual segmentation
  • +1 more outcomes

Companies that use Nucleo

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Nucleo technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Nucleo partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • NVIDIAcoreTechnology or IntegrationNVIDIA is listed as an industry leader powering Nucleo's technology. NVIDIA provides GPU computing infrastructure and likely AI/ML tools that support the company's CT scan analysis platform.
  • US HospitalscoreStrategic or Co-development PartnerNucleo works with leading hospitals in the US, deploying its automated cancer diagnostics technology in clinical oncology workflows.
  • International HospitalscoreStrategic or Co-development PartnerNucleo partners with hospitals worldwide, extending its automated cancer diagnostics platform to international healthcare markets.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Nucleo competitors and assessment

Company assessment

Direct peers

  • Annalise.ai: Annalise.ai provides comprehensive AI detection and quantification across CT and X-ray modalities, with oncology-relevant findings among its 130+ findings. Comparable in delivering CT AI analytics for hospital radiology and oncology workflows.
  • Viz.ai: Viz.ai provides AI-powered imaging analytics (notably stroke and oncology) that integrate into hospital workflows to triage and coordinate care. Comparable to Nucleo in deploying AI imaging models to hospital radiology/oncology teams and using subscription enterprise sales.
  • Aidoc: Aidoc is a leading AI radiology platform that analyzes CT and other imaging to flag acute findings (e.g., stroke, PE, oncology) for radiologists. Directly comparable to Nucleo in applying AI to CT scans for clinical oncology workflows and selling into hospital systems on a subscription basis.
  • Paige.AI: Paige applies AI to pathology and oncology imaging for cancer detection and tumor characterization, with FDA-cleared products. Directly comparable to Nucleo in using AI for cancer diagnostics from medical images and targeting oncology clinical workflows in hospitals.
  • Riverain Technologies (ClearRead): Riverain (ClearRead) offers AI tools that analyze chest CT and X-ray for nodule detection and improved reader efficiency, integrating into hospital PACS workflows. Comparable to Nucleo in applying AI to CT scans in oncology-relevant clinical workflows.
  • Arterys: Arterys (now Tempus AI Radiology) provides a cloud-native AI imaging analytics platform with FDA-cleared oncology and cardiac imaging applications. Comparable in delivering automated quantitative analysis of CT/MR images to hospital radiology departments via SaaS.
  • Perspectum: Perspectum develops AI-driven medical image quantification tools (e.g., body composition, organ fat/muscle) deployed in hospital and research settings. Comparable to Nucleo's body composition and quantitative oncology imaging analytics.
  • Quibim: Quibim is a medical imaging AI company that extracts quantitative biomarkers (including body composition and tumor characterization) from CT and MRI for oncology and other specialties. Closely comparable to Nucleo's body composition, tumor sizing, and lesion classification use cases.

Broad incumbents

  • RadNet (DeepHealth): RadNet operates one of the largest US imaging center networks and, through its DeepHealth subsidiary, develops AI tools for radiology including oncology. Comparable in deploying AI for CT scan analysis and oncology workflows, but as a large incumbent with diagnostic center operations.
  • Tempus AI: Tempus is a broad AI-driven precision medicine company spanning oncology data, sequencing, and imaging analytics (including Arterys). Comparable in applying AI to oncology imaging and clinical decision support, though operating at much larger scale across multiple modalities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key highlights6 records

Customer concentration

Nucleo social profiles

Digital presence

Nucleo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nucleo leadership team

Management profile

Number of profiles

Profiles3 records

Nucleo funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nucleo M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nucleo

What does Nucleo do?

Nucleo offers an AI-powered software platform that automates analysis of CT scans for oncology care. The platform performs three core functions: (1) automatic detection and quantification of body composition (fat and muscle mass) for sarcopenia assessment, (2) precise and consistent measurement of tumor lesions, and (3) automated classification of target vs. non-target lesions according to RECIST criteria. It is sold as a recurring software platform to hospitals and oncology providers, with reported 95% agreement between its outputs and expert radiologists.

Is Nucleo a public or private company?

Nucleo is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nucleo founded?

Nucleo was founded in 2025. It employs 1 to 10 people.

Where is Nucleo based?

Nucleo is headquartered in Singapore, Singapore, in the Asia region.

How does Nucleo make money?

One revenue line is on record: AI Diagnostics Platform.

Who are Nucleo's main competitors?

Direct peers on record are Annalise.ai, Viz.ai, Aidoc, Paige.AI, Riverain Technologies (ClearRead), Arterys, Perspectum and Quibim. Broad incumbents are RadNet (DeepHealth) and Tempus AI.

Does Nucleo have an API?

No public API is recorded for Nucleo.

What industry is Nucleo in?

Nucleo's product category is AI Oncology Imaging Software. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HLACALAK, Teleradiology Platforms & Reading Workflow. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals